|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-0.27/-0.20
|
企业价值
783.41M
|
资产负债 |
每股账面净值
3.33
|
现金流量 |
现金流量率
0.00
|
损益表 |
收益
169.02M
|
每股收益
3.22
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/12/23 22:20 EST
同行比较之报价最少15分钟延迟
业务概览
|
|||
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States. |